These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 803254)

  • 41. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disposition of salmeterol xinafoate in laboratory animals and humans.
    Manchee GR; Barrow A; Kulkarni S; Palmer E; Oxford J; Colthup PV; Maconochie JG; Tarbit MH
    Drug Metab Dispos; 1993; 21(6):1022-8. PubMed ID: 7905380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals.
    Schillings RT; Sisenwine SF
    Drug Metab Dispos; 1986; 14(4):405-12. PubMed ID: 2873986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacokinetics of pramiverine in rats, dogs, and monkeys (author's transl)].
    Steiner K; Diekmann HW; Garbe A; Nowak H
    Arzneimittelforschung; 1976 Apr; 26(4b):717-21. PubMed ID: 821494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Altered distribution and excretion of N-1-methylnicotinamide in rats with Walker 256 carcinosarcoma.
    Clark BR; Murai JT; Pomeranz A; Mills PA; Halpern RM
    Cancer Res; 1975 Jul; 35(7):1727-33. PubMed ID: 236826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
    Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
    Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
    [No Abstract]   [Full Text] [Related]  

  • 51. Disposition and metabolism of finasteride in dogs.
    Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
    Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents.
    Lowenthal IS; Parker LM; Greenblatt DJ; Brown BL; Samy TS
    Cancer Res; 1979 May; 39(5):1547-51. PubMed ID: 154972
    [No Abstract]   [Full Text] [Related]  

  • 53. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A direct ligand-binding radioassay for the measurement of methotrexate in tissues and biological fluids.
    Arons E; Rothenberg SP; Costa MD; Fischer C; Iqbal MP
    Cancer Res; 1975 Aug; 35(8):2033-8. PubMed ID: 807320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
    Selassie CD; Strong CD; Hansch C; Delcamp TJ; Freisheim JH; Khwaja TA
    Cancer Res; 1986 Feb; 46(2):744-56. PubMed ID: 3940640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates.
    Kimelberg HK; Biddlecome SM; Bourke RS
    Cancer Res; 1977 Jan; 37(1):157-65. PubMed ID: 401470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Half-life and metabolism of 3H-folic acid in oral contraceptive treated rats.
    Lakshmaiah N; Bamji MS
    Horm Metab Res; 1981 Jul; 13(7):404-7. PubMed ID: 7274995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Active-site directed irreversible inhibitors of dihydrofolate reductase.
    Baker BR
    Ann N Y Acad Sci; 1971 Nov; 186():214-26. PubMed ID: 4943574
    [No Abstract]   [Full Text] [Related]  

  • 59. Metabolism, disposition and excretion of [14C]melamine in male Fischer 344 rats.
    Mast RW; Jeffcoat AR; Sadler BM; Kraska RC; Friedman MA
    Food Chem Toxicol; 1983 Dec; 21(6):807-10. PubMed ID: 6686586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
    Nichol CA; Cavallito JC; Woolley JL; Sigel CW
    Cancer Treat Rep; 1977 Jul; 61(4):559-64. PubMed ID: 301777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.